Trial · NCT02698176
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 20 mg CRPC Cohort-Part A | 2 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 20 mg NMC Cohort-Part A | 1 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 20 mg TNBC Cohort-Part A | 0 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 20 mg CRPC Cohort-Part A | 9 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 20 mg NMC Cohort-Part A | 3 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 20 mg TNBC Cohort-Part A | 1 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 20 mg CRPC Cohort-Part A | 2 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 20 mg NMC Cohort-Part A | 0 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 20 mg TNBC Cohort-Part A | 0 | Participants | ||
| Objective Response Rate (ORR) | MK-8628 20 mg CRPC Cohort-Part A | 0 | Participants | ||
| Objective Response Rate (ORR) | MK-8628 20 mg NMC Cohort-Part A | 0 | Participants | ||
| Objective Response Rate (ORR) | MK-8628 20 mg TNBC Cohort-Part A | 0 | Participants | ||
| Disease Control Rate (DCR) | MK-8628 20 mg CRPC Cohort-Part A | 6 | Participants | ||
| Disease Control Rate (DCR) | MK-8628 20 mg NMC Cohort-Part A | 0 | Participants | ||
| Disease Control Rate (DCR) | MK-8628 20 mg TNBC Cohort-Part A | 0 | Participants | ||
| Observed Maximum Concentration (Cmax) of MK-8628 | MK-8628 20 mg PK Cohort | 355 | Standard Deviation 157 | ng/mL | |
| Observed Minimum Concentration (Cmin) of MK-8628 | MK-8628 20 mg PK Cohort | 111 | Standard Deviation 45.9 | ng/mL | |
| Time to Maximum Concentration (Tmax) of MK-8628 | MK-8628 20 mg PK Cohort | 2.25 | Full Range 1.00 to 3.25 | hours | |
| Apparent Terminal Half-Life (t1/2) of MK-8628 | MK-8628 20 mg PK Cohort | 6.17 | Standard Deviation 1.17 | hours | |
| Apparent Total Body Clearance (CL/F) of MK-8628 | MK-8628 20 mg PK Cohort | 6.44 | Standard Deviation 2.23 | Liters/hour |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02698176/results